Goldman Sachs’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Goldman Sachs’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-73,980	Closed	-$3.2M	–	7611
2015 Q3	$3.2M	Buy	73,980 +47,623	+181%	+$2.01M	﹤0.01%	3318
2015 Q2	$1.11M	Sell	26,357 -32,529	-55%	-$1.37M	﹤0.01%	4443
2015 Q1	$2.28M	Sell	58,886 -2,563	-4%	-$98.7K	﹤0.01%	3654
2014 Q4	$2.07M	Buy	61,449 +15,130	+33%	+$534K	﹤0.01%	3804
2014 Q3	$1.62M	Buy	46,319 +37,043	+399%	+$1.27M	﹤0.01%	4132
2014 Q2	$305K	Buy	9,276 +2,667	+40%	+$91.3K	﹤0.01%	5815
2014 Q1	$244K	Buy	+6,609	New	+$243K	﹤0.01%	5907
2013 Q4	–	Sell	-9,665	Closed	-$265K	–	6920
2013 Q3	$265K	Buy	+9,665	New	+$229K	﹤0.01%	5660

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Goldman Sachs's WX Position: Q4 2015 in Review

Goldman Sachs sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 73,980 shares — an estimated $3.2M sold.

Goldman Sachs first reported a position in WX in Q3 2013 and held it in 8 quarters. The position peaked at $3.2M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

Goldman Sachs reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
Goldman Sachs sold 73,980 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $3.2M.
Goldman Sachs first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 8 quarters.
Goldman Sachs's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.2M in Q3 2015.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Goldman Sachs's 13F filing for Q4 2015, filed 16 Feb 2016.